ALBANY, N.Y. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer and

ALBANY, N.Y. , Dec. 20, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 second

ALBANY, N.Y. , Nov. 28, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the pricing of the previously announced

ALBANY, N.Y. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that certain of its stockholders (the

New Senior Credit Facility Includes a $100 Million TLA and a $150 Million RCF Board of Directors Authorizes Up to $25 Million in Share Repurchases ALBANY, N.Y. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for

ALBANY, N.Y. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of Eileen Auen and Jan Stern Reed to the

ALBANY, N.Y. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

Q1 net sales of $88.1 million , up 5% year-over-year Q1 GAAP earnings per share of $0.04 ; non-GAAP adjusted EPS of $0.17 Q1 operating cash generation of $7.4 million FY2017 guidance remains unchanged ALBANY, N.Y. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider

ALBANY, N.Y. , Sept. 21, 2016 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 first

ALBANY, N.Y. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , Aug. 08, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Avista Capital Partners, LP and affiliated investment

AngioDynamics Issues Statement Regarding Stryker recall of Angiographic Catheters   ALBANY, N.Y., July 27, 2016 -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, issued

Greiner brings more than 20 years of accounting, corporate finance and operations experience from a variety of global corporations

Q4 Net sales of $93.4 million , up 3% year-over-year Q4 GAAP loss per share of $1.21 , inclusive of a one-time tax asset write down of $40.1 million ; Non-GAAP adjusted EPS of $0.19 , up 37% year-over-year Q4 Operating cash generation of $18.5 million FY2017 revenue guidance set at $355-$360

ALBANY, N.Y. , June 29, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 fourth

Net sales of $87.4 million , up 1% year-over-year GAAP earnings per share of $0.02 ; Non-GAAP adjusted EPS of $0.15 , up 25% year-over-year Operating cash generation of $12.4 million FY2016 financial guidance updated   ALBANY, N.Y. , April 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a

Clemmer brings more than 25 years of operational, manufacturing, marketing and business development experience in the global healthcare industry

ALBANY, N.Y. , March 29, 2016 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 third